• Oct 23, 2026

  $27.71-4.87%

  A Pr Newswire release promoting Hagens Berman said the company and certain executives faced a securities class action lawsuit [1]. The broad-market S&P 500 ETF (SPY) fell 0.52% in the same session, so the company's decline was far larger than the market's and was not shared by it [2].

  • 1Pr Newswire
  • 2Broad market

• Oct 22, 2026

  $29.13-0.27%

  Shares were nearly flat, down 0.27%. Rosen Law Firm and Pomerantz each issued press releases about a securities class action lawsuit against Hims & Hers [1][2].

  • 1Pr Newswire
  • 2Pr Newswire

• Oct 21, 2026

  $29.21+0.00%

  Robbins Geller and Hagens Berman each published notices about a securities class action against Hims & Hers [1]. Hagens Berman said certain company executives also faced the suit [2]. The shares closed flat, on volume of 0.6x the trailing average, within a session range of 28.85 to 29.92 [3].

  • 1Pr Newswire
  • 2Pr Newswire
  • 3Market data

• Oct 20, 2026

  $29.21+3.77%

  Seeking Alpha ran a headline saying Hims & Hers gained after a German launch [1]. The broad-market benchmark SPY rose 0.34% in the same session [2]. The company's 3.77% move was therefore much larger than the broad market's and was not shared by it [2].

  • 1Seeking Alpha
  • 2Broad market

• Oct 19, 2026

  $28.15+0.29%

• Oct 16, 2026

  $28.07-4.46%

  Hims & Hers shares fell 4.46% on a day the broad market also declined, with the S&P 500 ETF (SPY) down 1.11% [2]. The move was larger than the broad-market decline. Pr Newswire carried a Hagens Berman notice that a securities class action had been filed against the company and certain executives [1].

  • 1Pr Newswire
  • 2Broad market

• Oct 15, 2026

  $29.38+5.99%

  Hims & Hers rose 5.99% while the S&P 500 ETF (SPY) rose only 0.28%, so the move was not shared by the broad market [2]. Seeking Alpha reported that the stock rose as HHS moved ahead with a plan on compounding peptides, with a review of a policy letting compounding pharmacies make peptides like BPC-157 [1].

  • 1Seeking Alpha
  • 2Broad market

Closing prices for HIMS. Summaries describe past sessions only and are not advice, a forecast or a recommendation.

Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.